Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Haanen

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2011
[Issues around melanoma]John Haanen
Immuno-Oncology Technology|December 22, 2021
New milestones for IOTECH in 2022John Haanen
ESMO Open|August 20, 2019
Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugsJohn Haanen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2022
Minus Times Minus Equals PlusJohn Haanen, Solange Peters
World Journal of Urology|February 27, 2013
Do targeted agents offer clinical benefit as presurgical therapy?Axel Bex, John Haanen
Lancet (London, England)|November 8, 2011
Tilting the AXIS towards therapeutic limits in renal cancerAxel Bex, John Haanen
Nature Reviews. Clinical Oncology|July 4, 2018
Cytoreductive nephrectomy in metastatic renal cancer - less is moreAxel Bex, John Haanen
ESMO Open|June 25, 2019
How I treat MSI cancers with advanced diseaseMarleen Kok, Myriam Chalabi, John Haanen
The New England Journal of Medicine|November 9, 2018
Sunitinib Alone or after Nephrectomy in Renal CancerAxel Bex, Thomas Powles, John Haanen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 17, 2022
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage DiseaseElizabeth A Mittendorf, Femke Burgers, John Haanen, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Nederlands Tijdschrift Voor Geneeskunde|November 17, 2011
[Issues around melanoma]John Haanen
Immuno-Oncology Technology|December 22, 2021
New milestones for IOTECH in 2022John Haanen
ESMO Open|August 20, 2019
Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugsJohn Haanen
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2022
Minus Times Minus Equals PlusJohn Haanen, Solange Peters
World Journal of Urology|February 27, 2013
Do targeted agents offer clinical benefit as presurgical therapy?Axel Bex, John Haanen
Lancet (London, England)|November 8, 2011
Tilting the AXIS towards therapeutic limits in renal cancerAxel Bex, John Haanen
Nature Reviews. Clinical Oncology|July 4, 2018
Cytoreductive nephrectomy in metastatic renal cancer - less is moreAxel Bex, John Haanen
ESMO Open|June 25, 2019
How I treat MSI cancers with advanced diseaseMarleen Kok, Myriam Chalabi, John Haanen
The New England Journal of Medicine|November 9, 2018
Sunitinib Alone or after Nephrectomy in Renal CancerAxel Bex, Thomas Powles, John Haanen
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 17, 2022
Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage DiseaseElizabeth A Mittendorf, Femke Burgers, John Haanen, et al.
Pageof 7